JP2017501702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501702A5 JP2017501702A5 JP2016540620A JP2016540620A JP2017501702A5 JP 2017501702 A5 JP2017501702 A5 JP 2017501702A5 JP 2016540620 A JP2016540620 A JP 2016540620A JP 2016540620 A JP2016540620 A JP 2016540620A JP 2017501702 A5 JP2017501702 A5 JP 2017501702A5
- Authority
- JP
- Japan
- Prior art keywords
- tag
- gly
- fusion protein
- item
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 146
- 108020001507 fusion proteins Proteins 0.000 claims description 141
- 102000037865 fusion proteins Human genes 0.000 claims description 141
- 210000004027 cell Anatomy 0.000 claims description 82
- 239000012636 effector Substances 0.000 claims description 70
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 38
- 230000003834 intracellular effect Effects 0.000 claims description 34
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 30
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 30
- 230000002209 hydrophobic effect Effects 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 27
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 27
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 22
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 21
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 102100027207 CD27 antigen Human genes 0.000 claims description 19
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- -1 c-Met Proteins 0.000 claims description 17
- 102000005962 receptors Human genes 0.000 claims description 17
- 108020003175 receptors Proteins 0.000 claims description 17
- 210000004899 c-terminal region Anatomy 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 13
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 10
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 10
- 101000621309 Homo sapiens Wilms tumor protein Chemical group 0.000 claims description 10
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 10
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 9
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 claims description 9
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 9
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 5
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 5
- 102100035893 CD151 antigen Human genes 0.000 claims description 5
- 102100038078 CD276 antigen Human genes 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 5
- 108010065524 CD52 Antigen Proteins 0.000 claims description 5
- 102100027221 CD81 antigen Human genes 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 5
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 5
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 5
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 5
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 5
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 claims description 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 5
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 claims description 5
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 5
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 5
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 5
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 5
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 5
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 5
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 claims description 5
- 101000997535 Homo sapiens Growth hormone-releasing hormone receptor Proteins 0.000 claims description 5
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 5
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 5
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 5
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 5
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 5
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims description 5
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 5
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims description 5
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 5
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 5
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 5
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 5
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 5
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 5
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 5
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 5
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 5
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 5
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims description 5
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 claims description 5
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims description 5
- 102000003735 Mesothelin Human genes 0.000 claims description 5
- 108090000015 Mesothelin Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 102100023123 Mucin-16 Human genes 0.000 claims description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 5
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 5
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims description 5
- 108010065129 Patched-1 Receptor Proteins 0.000 claims description 5
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 5
- 102100028680 Protein patched homolog 1 Human genes 0.000 claims description 5
- 101150097792 Robo1 gene Proteins 0.000 claims description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims description 5
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims description 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 5
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 5
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 5
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 5
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 5
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 5
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 5
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 5
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 5
- 108060008724 Tyrosinase Proteins 0.000 claims description 5
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 5
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 5
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 5
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 5
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 5
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 4
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 4
- 102000000584 Calmodulin Human genes 0.000 claims description 4
- 108010041952 Calmodulin Proteins 0.000 claims description 4
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 4
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 4
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 108010071083 Patched-2 Receptor Proteins 0.000 claims description 4
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 4
- 102100036894 Protein patched homolog 2 Human genes 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 108060008226 thioredoxin Proteins 0.000 claims description 4
- 229940094937 thioredoxin Drugs 0.000 claims description 4
- 102100032912 CD44 antigen Human genes 0.000 claims description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 101100364669 Caenorhabditis elegans lin-18 gene Proteins 0.000 claims description 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 2
- 101100364671 Mus musculus Ryk gene Proteins 0.000 claims description 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims 2
- 101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 claims 1
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims 1
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 claims 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 1
- 101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 claims 1
- 108010029755 Notch1 Receptor Proteins 0.000 claims 1
- 108010029751 Notch2 Receptor Proteins 0.000 claims 1
- 108010029756 Notch3 Receptor Proteins 0.000 claims 1
- 108010029741 Notch4 Receptor Proteins 0.000 claims 1
- 102100036407 Thioredoxin Human genes 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 103
- 239000011159 matrix material Substances 0.000 description 14
- 230000004913 activation Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 102000043871 biotin binding protein Human genes 0.000 description 5
- 108700021042 biotin binding protein Proteins 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 239000002102 nanobead Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 108010058905 CD44v6 antigen Proteins 0.000 description 2
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000003333 near-infrared imaging Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021116355A JP2021164482A (ja) | 2013-12-20 | 2021-07-14 | タグ化キメラエフェクター分子およびそのレセプター |
| JP2022161138A JP2022176327A (ja) | 2013-12-20 | 2022-10-05 | タグ化キメラエフェクター分子およびそのレセプター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919201P | 2013-12-20 | 2013-12-20 | |
| US61/919,201 | 2013-12-20 | ||
| PCT/US2014/072007 WO2015095895A1 (en) | 2013-12-20 | 2014-12-22 | Tagged chimeric effector molecules and receptors thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038969A Division JP2019083821A (ja) | 2013-12-20 | 2019-03-04 | タグ化キメラエフェクター分子およびそのレセプター |
| JP2021116355A Division JP2021164482A (ja) | 2013-12-20 | 2021-07-14 | タグ化キメラエフェクター分子およびそのレセプター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501702A JP2017501702A (ja) | 2017-01-19 |
| JP2017501702A5 true JP2017501702A5 (enExample) | 2018-02-08 |
| JP6942467B2 JP6942467B2 (ja) | 2021-10-06 |
Family
ID=52396818
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540620A Active JP6942467B2 (ja) | 2013-12-20 | 2014-12-22 | タグ化キメラエフェクター分子およびそのレセプター |
| JP2019038969A Pending JP2019083821A (ja) | 2013-12-20 | 2019-03-04 | タグ化キメラエフェクター分子およびそのレセプター |
| JP2021116355A Pending JP2021164482A (ja) | 2013-12-20 | 2021-07-14 | タグ化キメラエフェクター分子およびそのレセプター |
| JP2022161138A Withdrawn JP2022176327A (ja) | 2013-12-20 | 2022-10-05 | タグ化キメラエフェクター分子およびそのレセプター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038969A Pending JP2019083821A (ja) | 2013-12-20 | 2019-03-04 | タグ化キメラエフェクター分子およびそのレセプター |
| JP2021116355A Pending JP2021164482A (ja) | 2013-12-20 | 2021-07-14 | タグ化キメラエフェクター分子およびそのレセプター |
| JP2022161138A Withdrawn JP2022176327A (ja) | 2013-12-20 | 2022-10-05 | タグ化キメラエフェクター分子およびそのレセプター |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10494434B2 (enExample) |
| EP (1) | EP3083671B1 (enExample) |
| JP (4) | JP6942467B2 (enExample) |
| KR (2) | KR102483822B1 (enExample) |
| CN (2) | CN105980402B (enExample) |
| AU (3) | AU2014368892B2 (enExample) |
| BR (1) | BR112016014156A8 (enExample) |
| CA (1) | CA2933707A1 (enExample) |
| CY (1) | CY1123747T1 (enExample) |
| DK (1) | DK3083671T3 (enExample) |
| ES (1) | ES2837856T3 (enExample) |
| HR (1) | HRP20201906T1 (enExample) |
| HU (1) | HUE052573T2 (enExample) |
| IL (1) | IL245845B (enExample) |
| LT (1) | LT3083671T (enExample) |
| MX (1) | MX386422B (enExample) |
| MY (1) | MY178233A (enExample) |
| NZ (2) | NZ720520A (enExample) |
| PL (1) | PL3083671T3 (enExample) |
| PT (1) | PT3083671T (enExample) |
| RS (1) | RS61223B1 (enExample) |
| RU (1) | RU2729463C2 (enExample) |
| SG (2) | SG10201804439PA (enExample) |
| SI (1) | SI3083671T1 (enExample) |
| SM (1) | SMT202000699T1 (enExample) |
| WO (1) | WO2015095895A1 (enExample) |
Families Citing this family (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606970UA (en) | 2012-02-23 | 2016-10-28 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| PL3083671T3 (pl) * | 2013-12-20 | 2021-03-22 | Fred Hutchinson Cancer Center | Znakowane chimeryczne cząsteczki efektorowe i ich receptory |
| US10323077B2 (en) * | 2014-02-10 | 2019-06-18 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| CA2942245C (en) | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR102714469B1 (ko) | 2014-04-16 | 2024-10-11 | 주노 테라퓨틱스 게엠베하 | 세포 집단의 증대를 위한 방법, 키트 및 장치 |
| MX382541B (es) | 2014-04-23 | 2025-03-13 | Juno Therapeutics Inc | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. |
| SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
| EP3172228B1 (en) * | 2014-07-25 | 2019-02-27 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| GB201415344D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| CN107406516B (zh) * | 2015-01-26 | 2021-11-23 | 塞勒克提斯公司 | 用于癌症免疫治疗的抗CLL1特异性单链嵌合抗原受体(scCAR) |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2017075571A1 (en) | 2015-10-30 | 2017-05-04 | Children's National Medical Center | Generating hpv antigen-specific cells from a naive t cell population |
| GB201504840D0 (en) * | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| EP3288569A4 (en) * | 2015-04-29 | 2018-12-19 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| PT3298033T (pt) | 2015-05-18 | 2020-09-22 | Tcr2 Therapeutics Inc | Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| EP3575403A1 (en) * | 2015-08-05 | 2019-12-04 | Yoo Young Pharm Co., Ltd. | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed |
| CN108350062B (zh) | 2015-08-06 | 2022-10-14 | 达纳-法伯癌症研究所股份有限公司 | 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应 |
| EP3355937A4 (en) | 2015-09-28 | 2019-04-17 | Regents of the University of Minnesota | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| RU2761555C2 (ru) | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| MX2018005315A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| EP3407919A4 (en) * | 2016-01-28 | 2019-09-04 | The Regents of the University of California | METHOD FOR THE SELECTIVE EXPANSION AND ENRICHMENT OF CELLS TRANSDUCED WITH CHIMERIC ANTIGEN RECEPTORS AND TREATMENT OF HIV INFECTION |
| KR102366611B1 (ko) | 2016-03-18 | 2022-02-23 | 프레드 헛친슨 켄서 리서치 센터 | Cd20 면역요법을 위한 조성물 및 방법 |
| CN109415409B (zh) | 2016-04-01 | 2022-03-15 | 亘喜生物科技（上海）有限公司 | Flag标记的cd19-car-t细胞 |
| CN106399255B (zh) * | 2016-04-13 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Pd-1 car-t细胞及其制备方法和应用 |
| AU2017251116A1 (en) * | 2016-04-15 | 2018-12-06 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| CN105907719B (zh) * | 2016-04-18 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Anti ROBO1 CAR-T细胞及其制备和应用 |
| US11339225B2 (en) | 2016-05-12 | 2022-05-24 | Asclepius (Suzhou) Technology Company Group, Co., Ltd. | Bispecific antigen-binding construct and preparation method and use thereof |
| CN107365387B (zh) * | 2016-05-12 | 2022-03-15 | 阿思科力(苏州)生物科技有限公司 | 一种双特异性抗原结合构建体及其制备方法和应用 |
| WO2017201281A1 (en) * | 2016-05-18 | 2017-11-23 | Mayo Foundation For Medical Education And Research | Targeting pd-l1 on tumor cells |
| CN107522786A (zh) * | 2016-06-20 | 2017-12-29 | 深圳市体内生物医药科技有限公司 | 一种分子、表达其的细胞及其制备方法和用途 |
| MX2019000641A (es) * | 2016-07-15 | 2019-06-10 | Poseida Therapeutics Inc | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. |
| CA3031289A1 (en) * | 2016-07-18 | 2018-01-25 | Helix Biopharma Corp. | Car immune cells to treat cancer |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| AU2017307610B2 (en) | 2016-08-04 | 2023-10-05 | Memorial Sloan-Kettering Cancer Center | Cancer antigen targets and uses thereof |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CN110139669A (zh) | 2016-11-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | T细胞疗法和btk抑制剂的组合疗法 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN110248678A (zh) | 2016-12-03 | 2019-09-17 | 朱诺治疗学股份有限公司 | 调节car-t细胞的方法 |
| CN106701827A (zh) * | 2016-12-05 | 2017-05-24 | 刘晓明 | 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法 |
| EP3555273B1 (en) * | 2016-12-16 | 2024-05-22 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| WO2018128486A1 (ko) * | 2017-01-05 | 2018-07-12 | 한국생명공학연구원 | Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체 |
| AU2018209400B2 (en) | 2017-01-20 | 2022-06-02 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| EP3580212A4 (en) | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| EP3580568A1 (en) | 2017-02-09 | 2019-12-18 | Fred Hutchinson Cancer Research Center | Biomarkers and uses thereof for selecting immunotherapy intervention |
| CA3052779A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| CN110636851B (zh) | 2017-03-27 | 2023-11-03 | 新加坡国立大学 | 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| JP7284707B2 (ja) | 2017-04-07 | 2023-05-31 | ジュノー セラピューティクス インコーポレイテッド | 前立腺特異的膜抗原（ｐｓｍａ）またはその改変型を発現する操作された細胞および関連方法 |
| ES3038614T3 (en) | 2017-04-27 | 2025-10-14 | Juno Therapeutics Inc | Oligomeric particle reagents and methods of use thereof |
| US10858443B2 (en) * | 2017-05-31 | 2020-12-08 | Trustees Of Boston University | Synthetic notch protein for modulating gene expression |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN107098969B (zh) * | 2017-06-28 | 2018-10-12 | 武汉波睿达生物科技有限公司 | 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用 |
| CN107541499B (zh) * | 2017-07-27 | 2020-04-14 | 山东兴瑞生物科技有限公司 | 一种靶向免疫检测点tnfr2的cik的制备及其应用 |
| AU2018314242A1 (en) * | 2017-08-11 | 2020-02-13 | Fred Hutchinson Cancer Center | BRAF-specific TCRs and uses thereof |
| US20200299340A1 (en) * | 2017-08-25 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Fusion proteins comprising detectable tags, nucleic acid molecules, and method of tracking a cell |
| EP3679072A1 (en) * | 2017-09-06 | 2020-07-15 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
| CA3072908A1 (en) * | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific binding proteins and uses thereof |
| US20200292526A1 (en) | 2017-09-07 | 2020-09-17 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| WO2019079486A1 (en) | 2017-10-18 | 2019-04-25 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS |
| CN109706120A (zh) * | 2017-10-26 | 2019-05-03 | 深圳宾德生物技术有限公司 | 一种双靶点特异性t淋巴细胞及其制备方法和应用 |
| DK3703750T3 (da) | 2017-11-01 | 2025-02-10 | Juno Therapeutics Inc | Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider |
| EP4512823A3 (en) | 2017-11-01 | 2025-05-14 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| KR20200099137A (ko) | 2017-11-06 | 2020-08-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법 및 감마 세크레타제 억제제의 조합 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN111655732B (zh) | 2017-11-14 | 2023-09-12 | Gc细胞治疗 | 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体 |
| CN109810995B (zh) * | 2017-12-06 | 2020-10-02 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
| MX2020005906A (es) | 2017-12-08 | 2020-10-22 | Juno Therapeutics Inc | Marcadores fenotipicos para terapia celular y metodos relacionados. |
| SG11202005228YA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Serum-free media formulation for culturing cells and methods of use thereof |
| KR20200128014A (ko) | 2018-01-31 | 2020-11-11 | 셀진 코포레이션 | 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법 |
| US12338459B2 (en) | 2018-02-02 | 2025-06-24 | Arizona Board Of Regents On Behalf Of Arizona State University | DNA-chimeric antigen receptor T cells for immunotherapy |
| CA3089170A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019157496A1 (en) * | 2018-02-12 | 2019-08-15 | University Of Florida Researchfoundation, Inc. | Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a |
| EP3759130A1 (en) * | 2018-02-26 | 2021-01-06 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| CN112955184A (zh) * | 2018-03-15 | 2021-06-11 | 基本解决方案公司 | 可编程免疫细胞受体复合物系统 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019213184A1 (en) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| WO2019232425A1 (en) | 2018-06-01 | 2019-12-05 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| US20210223248A1 (en) | 2018-06-01 | 2021-07-22 | Fred Hutchinson Cancer Research Center | Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods |
| WO2019241557A1 (en) * | 2018-06-15 | 2019-12-19 | The Regents Of The University Of California | Fusion fragment chimeric antigen receptors and uses thereof |
| MX2021001523A (es) * | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Procesos para generar células modificadas y composiciones de las mismas. |
| CR20210127A (es) | 2018-08-10 | 2021-04-19 | Chugai Pharmaceutical Co Ltd | Molécula de unión al antigeno anti grupo de diferenciación 137 (cd137) y su uso |
| CN110856724B (zh) * | 2018-08-24 | 2022-05-27 | 杭州康万达医药科技有限公司 | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CN109136244A (zh) * | 2018-08-31 | 2019-01-04 | 河北璋达生物科技有限公司 | 一种可诱导凋亡的携带检测标签的cd20嵌合抗原受体t淋巴细胞及其应用 |
| EP3847188A1 (en) * | 2018-09-03 | 2021-07-14 | Technische Universität München | A double peptide tag combining reversibility and flexible functionalization |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| SG11202105084VA (en) | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| CN109467598B (zh) * | 2018-11-28 | 2021-11-09 | 生命谷（海南）生物科技股份有限公司 | 肿瘤相关基因notch1突变短肽及其应用 |
| DK3886894T3 (da) | 2018-11-30 | 2024-06-03 | Juno Therapeutics Inc | Fremgangsmåder til dosering og behandling af b-cellemaligniteter i adoptiv celleterapi |
| ES2981569T3 (es) | 2018-11-30 | 2024-10-09 | Juno Therapeutics Inc | Métodos de tratamiento usando terapia celular adoptiva |
| CA3123303A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CA3132916A1 (en) | 2019-03-11 | 2020-09-17 | Janssen Biotech, Inc. | Anti-v.beta.17/anti-cd123 bispecific antibodies |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| JP2022537700A (ja) | 2019-06-12 | 2022-08-29 | ジュノー セラピューティクス インコーポレイテッド | 細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法 |
| CN110358734B (zh) * | 2019-06-13 | 2020-08-25 | 首都医科大学宣武医院 | 以Tcm为主要效应成分的CAR-T制备方法及其应用 |
| CA3144951A1 (en) | 2019-07-03 | 2021-01-07 | Peptidream Inc. | Cd38-binding agents and uses thereof |
| US20210040174A1 (en) * | 2019-08-08 | 2021-02-11 | Navrogen, Inc. | Composition and Use of Humoral Immune Suppressor Antagonists for the Treatment of Humoral Immune Suppressed Diseases |
| US20220401537A1 (en) * | 2019-09-16 | 2022-12-22 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| FI4034252T3 (fi) * | 2019-09-24 | 2025-01-30 | Univ California | Saranadomeenin sisältäviä Notch-reseptoreita |
| KR20220122615A (ko) | 2019-11-07 | 2022-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 요법 및 (ｓ)-3-[4-(4-모르폴린-4-일메틸-벤질옥시)-1-옥소-1,3-디하이드로-이소인돌-2-일]-피페리딘-2,6-디온의 병용 |
| CN110734931A (zh) * | 2019-11-18 | 2020-01-31 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种靶向CD19的人源化scFv嵌合抗原受体T细胞及制备方法、应用 |
| WO2021101349A1 (ko) * | 2019-11-21 | 2021-05-27 | 에이비엘바이오 주식회사 | Ror1 및 b7-h3에 결합하는 항체, 이를 포함하는 항체-약물 접합체 및 그 용도 |
| CN113677704B (zh) * | 2019-11-22 | 2024-03-26 | 南通壹宸生物医药科技有限公司 | Psma抗体及其应用 |
| IL293393A (en) | 2019-12-06 | 2022-07-01 | Juno Therapeutics Inc | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| EP4093433A1 (en) | 2020-01-24 | 2022-11-30 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
| BR112022015236A2 (pt) | 2020-02-12 | 2022-09-20 | Juno Therapeutics Inc | Composições de células t do receptor de antígeno quimérico direcionado a cd19 e métodos e usos das mesmas |
| CA3170369A1 (en) | 2020-03-05 | 2022-04-14 | Michal Shahar | Methods and compositions for treating cancer with immune cells |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN119264269A (zh) * | 2020-03-25 | 2025-01-07 | 北京艺妙神州医药科技有限公司 | 结合cd19的嵌合抗原受体及其用途 |
| EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| CN111848797B (zh) * | 2020-07-20 | 2021-02-09 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| KR20230084508A (ko) | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 |
| PE20231210A1 (es) | 2020-10-19 | 2023-08-17 | Zoetis Services Llc | Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos |
| AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| KR102671408B1 (ko) * | 2021-02-26 | 2024-06-04 | 진화섭 | HLA class II에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| MX2023011370A (es) | 2021-03-29 | 2023-11-24 | Juno Therapeutics Inc | Combinacion de una terapia con celulas t con receptores de antigenos quimericos (car) y un compuesto inmunomodulador para el tratamiento de linfoma. |
| JP2024514245A (ja) | 2021-03-29 | 2024-03-29 | ジュノー セラピューティクス インコーポレイテッド | チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法 |
| EP4319794A4 (en) * | 2021-04-08 | 2025-03-12 | Artiva Biotherapeutics, Inc. | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING SAME |
| CN113549158B (zh) * | 2021-07-19 | 2022-10-21 | 广州百暨基因科技有限公司 | 包含突变型il15以及嵌合抗原受体的融合蛋白 |
| US20240361700A1 (en) | 2021-10-06 | 2024-10-31 | Asahi Kasei Kabushiki Kaisha | Method for producing printing plate and printing method |
| EP4426722A4 (en) * | 2021-11-02 | 2025-12-10 | Fred Hutchinson Cancer Center | CANCER TREATMENTS USING CELL-TARGETING THERAPIES AND ASSOCIATED RESEARCH PROTOCOLS |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| KR20250061756A (ko) | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| TW202502363A (zh) | 2023-02-28 | 2025-01-16 | 美商奇諾治療有限公司 | 用於治療全身性自體免疫疾病之細胞療法 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| WO2025100965A1 (ko) * | 2023-11-07 | 2025-05-15 | 주식회사 박셀바이오 | EphA2를 타겟하는 개선된 특성을 갖는 친수성 모노바디 및 이를 포함하는 다중특이적 키메라 항원 수용체 및 조작된 면역세포 |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| KR20250074841A (ko) * | 2023-11-20 | 2025-05-28 | (재) 스크립스코리아항체연구원 | 키메라 항원 수용체를 발현하는 면역 세포 및 트렙타비딘 스캐폴드 항체 유사 단백질을 포함하는 항암용 조성물, 및 이의 용도 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| JP4137997B2 (ja) | 1994-01-11 | 2008-08-20 | ダイアックス コープ． | クニッツドメインから誘導されたヒトプラスミンの阻害剤 |
| ATE297986T1 (de) * | 1995-02-24 | 2005-07-15 | Gen Hospital Corp | Neuorientierung der zellulären immunität durch rezeptorchimären |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| US6303373B1 (en) * | 1999-06-09 | 2001-10-16 | Whitehead Institute For Biomedical Research | Method of measuring plasma membrane targeting of GLUT4 |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| DE69919515T2 (de) * | 1998-02-23 | 2005-04-07 | Ark Therapeutics Ltd. | Biotinbindende rezeptormoleküle |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| BR9912662A (pt) | 1998-07-31 | 2001-06-05 | Genzyme Corp | Melhoria de função cardìaca por transplante de célula de ramo mesenquimal |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| AU781396B2 (en) | 1999-07-20 | 2005-05-19 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002059285A1 (en) | 2000-10-27 | 2002-08-01 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
| EP1227321A1 (en) * | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| AU2002315337A1 (en) | 2001-06-18 | 2003-01-02 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using valproate |
| DE10137792A1 (de) | 2001-08-06 | 2003-02-27 | Erdmann Volker | Verfahren zur Genexpression |
| JP4906231B2 (ja) | 2001-09-14 | 2012-03-28 | ステム セル セラピューティクス インコーポレイテッド | プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途 |
| EP1435779A4 (en) | 2001-09-24 | 2005-06-01 | Sangamo Biosciences Inc | MODULATION OF STEM CELLS USING ZINC FINGER PROTEINS (ZFP) |
| WO2003078619A1 (en) | 2002-03-15 | 2003-09-25 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| AU2003250705A1 (en) | 2002-07-31 | 2004-02-16 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
| EP1400534B1 (en) | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
| US7575925B2 (en) | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
| JP2006518372A (ja) | 2003-01-28 | 2006-08-10 | セレクティス | 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用 |
| US7368428B2 (en) | 2003-06-23 | 2008-05-06 | A&G Pharmaceutical, Inc. | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| WO2006000830A2 (en) | 2004-06-29 | 2006-01-05 | Avidex Ltd | Cells expressing a modified t cell receptor |
| ATE414718T1 (de) | 2005-01-05 | 2008-12-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| US8021867B2 (en) | 2005-10-18 | 2011-09-20 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
| US20090220501A1 (en) | 2006-01-30 | 2009-09-03 | Fey Georg H | Anti-CD19 Antibody, Immunotoxin and Treatment Method |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| EP1878744A1 (en) | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US9387226B2 (en) | 2006-11-30 | 2016-07-12 | Medipost Co., Ltd | Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells |
| EP2126052B1 (en) | 2007-01-09 | 2014-12-10 | Lead Pharma Cel Models IP B.V. | Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom |
| US20090042795A1 (en) | 2007-06-05 | 2009-02-12 | Pasan Fernando | Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation |
| US9365629B2 (en) | 2007-09-24 | 2016-06-14 | University Of Zurich | Designed armadillo repeat proteins |
| KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| AU2009298192B2 (en) | 2008-10-03 | 2015-01-22 | Xoma Technology Ltd. | Novel triple tag sequences and methods of use thereof |
| CA3092340A1 (en) | 2008-11-21 | 2010-05-27 | Universiteit Stellenbosch | Yeast expressing cellulases for simultaneous saccharification and fermentation using cellulose |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2424882A2 (en) * | 2009-02-05 | 2012-03-07 | Intercell AG | Peptides protective against e. faecalis, methods and uses relating thereto |
| DK2419447T3 (en) | 2009-04-17 | 2017-09-25 | Immunas Pharma Inc | ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| WO2011041093A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| JP2013517761A (ja) * | 2010-01-21 | 2013-05-20 | オキシレイン ユーケー リミテッド | 酵母細胞の表面上にポリペプチドをディスプレイするための方法および組成物 |
| GB201008682D0 (en) | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| US20130315962A1 (en) | 2010-07-06 | 2013-11-28 | Nanologica Ab | Method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmceutical active ingredients |
| EP2614151B1 (en) | 2010-09-08 | 2019-07-24 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| US20120107282A1 (en) | 2010-10-01 | 2012-05-03 | S. Biomedics Co., Ltd. | Neural stem cell composition capable of treating cancer and method of treatment |
| WO2012068378A1 (en) | 2010-11-17 | 2012-05-24 | Wake Forest University Health Sciences | Stem cell differentiation using keratin biomaterials |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3102782A1 (en) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| WO2012127464A2 (en) * | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| SMT201700025T1 (it) | 2011-04-13 | 2017-03-08 | Bristol Myers Squibb Co | Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti |
| US20120308530A1 (en) | 2011-06-03 | 2012-12-06 | Beijing Allgens Medical Science & Technology Co., Ltd. | Materials Composition and Methods to Control Neural Progenitor and Stem Cell Attachment, Proliferation and Guide Cell Differentiation |
| AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
| US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| US9717761B2 (en) | 2011-11-21 | 2017-08-01 | Ramot At Tel-Aviv University Ltd. | Stem cell-derived neural cells for cell therapy in neurological disorders |
| US9649358B2 (en) | 2011-12-12 | 2017-05-16 | The Regents Of The University Of California | Methods for use of neural stem cell compositions for treatment of central nervous system lesions |
| KR101996343B1 (ko) | 2012-01-27 | 2019-07-05 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 전능성 줄기세포의 심근분화 유도방법 |
| US9447194B2 (en) | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| SG10201606970UA (en) | 2012-02-23 | 2016-10-28 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| WO2013176772A1 (en) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| MX380109B (es) | 2012-08-20 | 2025-03-12 | Fred Hutchinson Cancer Center Star | Metodo y composiciones para inmunoterapia celular. |
| DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014100483A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anti-human b7-h4 antibodies and their uses |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| HK1223943A1 (zh) | 2013-05-24 | 2017-08-11 | Board Of Regents, The University Of Texas System | 嵌合的靶向抗原受体的单克隆抗体 |
| WO2014201431A1 (en) | 2013-06-14 | 2014-12-18 | Massachusetts Institute Of Technology | Articles and methods for stem cell differentiation |
| CN105873952A (zh) | 2013-10-31 | 2016-08-17 | 弗莱德哈钦森癌症研究中心 | 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途 |
| EP2871189A1 (en) | 2013-11-07 | 2015-05-13 | Institut Pasteur | High-affinity monoclonal anti-strep-tag antibody |
| EP3071695A2 (en) | 2013-11-18 | 2016-09-28 | Crispr Therapeutics AG | Crispr-cas system materials and methods |
| RU2717984C2 (ru) | 2013-11-21 | 2020-03-27 | ЮСиЭл БИЗНЕС ЛТД | Клетка |
| PL3083671T3 (pl) * | 2013-12-20 | 2021-03-22 | Fred Hutchinson Cancer Center | Znakowane chimeryczne cząsteczki efektorowe i ich receptory |
| EP3626748A1 (en) | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| AR101848A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos de anti-b7-h4 e inmunoconjugados |
| BR112017006825A2 (pt) | 2014-10-03 | 2017-12-12 | Dana Farber Cancer Inst Inc | anticorpos contra receptor do fator de necrose tumoral induzido por glicocorticoides (gitr) e seus métodos de utilização |
| PL3258951T3 (pl) | 2015-02-19 | 2020-07-27 | Compugen Ltd. | Przeciwciała anty-pvrig i sposoby ich zastosowania |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| EP3288569A4 (en) | 2015-04-29 | 2018-12-19 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| AU2018209400B2 (en) | 2017-01-20 | 2022-06-02 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| CA3072908A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific binding proteins and uses thereof |
| EP3679072A1 (en) | 2017-09-06 | 2020-07-15 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
-
2014
- 2014-12-22 PL PL14830770.5T patent/PL3083671T3/pl unknown
- 2014-12-22 ES ES14830770T patent/ES2837856T3/es active Active
- 2014-12-22 BR BR112016014156A patent/BR112016014156A8/pt not_active Application Discontinuation
- 2014-12-22 SM SM20200699T patent/SMT202000699T1/it unknown
- 2014-12-22 JP JP2016540620A patent/JP6942467B2/ja active Active
- 2014-12-22 SG SG10201804439PA patent/SG10201804439PA/en unknown
- 2014-12-22 AU AU2014368892A patent/AU2014368892B2/en active Active
- 2014-12-22 CN CN201480075007.8A patent/CN105980402B/zh active Active
- 2014-12-22 CA CA2933707A patent/CA2933707A1/en active Pending
- 2014-12-22 RS RS20201392A patent/RS61223B1/sr unknown
- 2014-12-22 SI SI201431722T patent/SI3083671T1/sl unknown
- 2014-12-22 WO PCT/US2014/072007 patent/WO2015095895A1/en not_active Ceased
- 2014-12-22 KR KR1020167017510A patent/KR102483822B1/ko active Active
- 2014-12-22 HR HRP20201906TT patent/HRP20201906T1/hr unknown
- 2014-12-22 RU RU2016129045A patent/RU2729463C2/ru active
- 2014-12-22 NZ NZ720520A patent/NZ720520A/en unknown
- 2014-12-22 MX MX2016007927A patent/MX386422B/es unknown
- 2014-12-22 CN CN202110592499.XA patent/CN113354744A/zh active Pending
- 2014-12-22 DK DK14830770.5T patent/DK3083671T3/da active
- 2014-12-22 PT PT148307705T patent/PT3083671T/pt unknown
- 2014-12-22 MY MYPI2016001073A patent/MY178233A/en unknown
- 2014-12-22 KR KR1020227046118A patent/KR20230007559A/ko not_active Abandoned
- 2014-12-22 EP EP14830770.5A patent/EP3083671B1/en active Active
- 2014-12-22 LT LTEP14830770.5T patent/LT3083671T/lt unknown
- 2014-12-22 SG SG11201605046YA patent/SG11201605046YA/en unknown
- 2014-12-22 NZ NZ759969A patent/NZ759969A/en unknown
- 2014-12-22 HU HUE14830770A patent/HUE052573T2/hu unknown
- 2014-12-22 US US15/106,657 patent/US10494434B2/en active Active
-
2016
- 2016-05-25 IL IL245845A patent/IL245845B/en active IP Right Grant
-
2019
- 2019-03-04 JP JP2019038969A patent/JP2019083821A/ja active Pending
- 2019-09-13 AU AU2019229438A patent/AU2019229438B2/en active Active
- 2019-10-25 US US16/664,706 patent/US11046766B2/en active Active
-
2020
- 2020-12-23 CY CY20201101218T patent/CY1123747T1/el unknown
-
2021
- 2021-05-24 US US17/329,115 patent/US11993652B2/en active Active
- 2021-06-29 AU AU2021204475A patent/AU2021204475B2/en active Active
- 2021-07-14 JP JP2021116355A patent/JP2021164482A/ja active Pending
-
2022
- 2022-10-05 JP JP2022161138A patent/JP2022176327A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501702A5 (enExample) | ||
| RU2016129045A (ru) | Меченые химерные эффекторные молекулы и их рецепторы | |
| CN111263641B (zh) | 用于制备基因工程化细胞的方法和组合物 | |
| Oren et al. | Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody–based chimeric antigen receptors indicates affinity/avidity thresholds | |
| KR102488477B1 (ko) | 신속하고 포괄적인 t-세포 면역 모니터링을 위한 세포 플랫폼 | |
| US11180553B2 (en) | Chimeric antigen receptor | |
| JP2023036657A (ja) | 修飾されたｔ細胞及びその使用方法 | |
| CN116194130A (zh) | 新颖的抗原结合结构域和包含这些抗原结合结构域的合成抗原受体 | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| KR20200015713A (ko) | 항-trbc1 항원 결합 도메인 | |
| CN110730908A (zh) | 表达前列腺特异性膜抗原（psma）或其修饰形式的工程化细胞及相关方法 | |
| JP2019503200A (ja) | 癌の治療のための組成物及び方法 | |
| JP2018521628A5 (enExample) | ||
| JP2018532432A5 (enExample) | ||
| JP2015524255A (ja) | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 | |
| CN110637033A (zh) | 用于治疗癌症的组合物和方法 | |
| de Bruin et al. | Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications | |
| JP7429882B2 (ja) | キメラ抗原受容体を発現する粘膜関連インバリアントｔ（ｍａｉｔ）細胞 | |
| CN111246862A (zh) | 产生基因工程化细胞组合物的方法和相关组合物 | |
| CN111819186A (zh) | 表达嵌合抗原受体的免疫细胞 | |
| JP2020535796A5 (enExample) | ||
| JP2025107358A (ja) | 細胞 | |
| US20230167184A1 (en) | Bcma-specific antibody and chimeric antigen receptor | |
| KR20220083667A (ko) | 압타머 기반의 다중특이 치료제 | |
| CN119613563A (zh) | 编码car的核酸分子和含其的载体、car、含car的免疫细胞及其制造方法和含该细胞的医药组合物及提升细胞损伤活性的方法 |